Close
RNS Number : 4627Z
Hikma Pharmaceuticals Plc
17 May 2019
 

 

Hikma Pharmaceuticals PLC

Voting Results of 2019 Annual General Meeting

LONDON, 17 May 2019 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 17 May 2019 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 16 were passed as ordinary resolutions and Resolutions 17 to 20 were passed as special resolutions.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 15 April 2019) is set out below. The number of Ordinary Shares in issue on 17 May 2019 was 242,013,996.

Resolution

Votes For

%

Votes Against

%

Total Cast

Withheld

1. To receive the 2018 report and accounts

198,016,257

99.99

15,248

0.01

198,031,505

145,325

2. To approve a final dividend of 26 cents per share

198,172,485

100.00

437

0.00

198,172,922

3,909

3. To re-appoint PricewaterhouseCoopers LLP as auditors

198,168,429

100.00

2,171

0.00

198,170,600

6,231

4.To authorise the Audit Committee to determine the auditors' remuneration

198,169,496

100.00

1,989

0.00

198,171,485

5,346

5. To re-elect Said Darwazah as a director

191,458,492

96.61

6,712,792

3.39

198,171,284

5,546

6. To re-elect Siggi Olafsson as a director

194,921,594

98.36

3,251,178

1.64

198,172,772

4,059

7. To re-elect Mazen Darwazah as a director

191,501,356

96.63

6,670,679

3.37

198,172,035

4,796

8. To re-elect Robert Pickering as a director

186,397,645

94.06

11,763,463

5.94

198,161,108

15,722

9.To re-elect Ali Al-Husry as a director

189,606,735

95.68

8,564,549

4.32

198,171,284

5,546

10. To re-elect Patrick Butler as a director

194,287,800

98.04

3,883,484

1.96

198,171,284

5,546

11. To re-elect Dr. Pamela Kirby as a director

182,139,906

91.91

16,032,128

8.09

198,172,034

4,796

12. To re-elect Dr. Jochen Gann as a director

194,395,430

98.09

3,775,854

1.91

198,171,284

5,546

13. To re-elect John Castellani as a director

195,035,397

98.42

3,135,888

1.58

198,171,285

5,546

14. To re-elect Nina Henderson as a director

194,490,204

98.14

3,681,830

1.86

198,172,034

4,796

15. To approve the remuneration report for the year ended 31 December 2018

190,476,075

96.12

7,695,409

3.88

198,171,484

5,346

16. Authority to allot shares

168,835,150

85.20

29,337,771

14.80

198,172,921

3,909

17. To dis-apply pre-emption rights for general purposes

198,116,024

99.97

56,161

0.03

198,172,185

4,646

18. To dis-apply pre-emption rights for an acquisition or other capital investment

195,242,802

98.52

2,929,382

1.48

198,172,184

4,646

19. To authorise the Company to purchase its own shares

197,396,007

99.66

682,740

0.34

198,078,747

98,083

20. To authorise the Company to hold general meetings on no less than 14 clear days' notice

187,234,093

94.48

10,936,803

5.52

198,170,896

5,785

 

Declaration of final dividend

The dividend of 26 cents per share will be paid on 22 May 2019 to shareholders on the register on 5 April 2019.  Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling.  The exchange rate in respect of this dividend will be $1.2928 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.

- ENDS -

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Peter Speirs

Company Secretary

 

+44 20 7399 2670

Susan Ringdal

EVP, Strategic Planning and Global Affairs

 

+44 20 7399 2670

 

 

 

 

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.  For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

 

LEI: 549300BNS685UXH4JI75


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGSFWFIWFUSESI